Treatment of skin disorders

Claim 1

A method for the treatment of a skin disorder in man and other mammals selected from the group consisting of: Ichthyosiform dermatoses, Conradi's syndrome, Localised hyperkeratotic conditions, Dandruff, Callous-forming disorders, Psoriasis, Eczema, Xerosis, Warts, Dermatomycoses, Pityriasis rosea and Pityriasis alba, Lichen planus and Lichen simplex chronicus, Cicatricial alopecia with dry flaky scalp, Darier's disease, Pruritus, Seborrhoeic dermatitis, Seborrhoeic eczema, Acne, and Scabies, said method comprising applying to involved areas of the body a composition comprising: (i) an effective amount of an ester of pyroglutamic acid having the structure: ##STR4## where R is a group: ##STR5## ##STR6## where R' and R" are the same or different and are each represented by H or the group: [(CH.sub.3).sub.u,(CH.sub.2 OH).sub.v, (CH.sub.2).sub.w,(CHCH.sub.3).sub.x,(CHOH).sub.y,(CH═CH).sub.z]--( 2) where either u or v is 1 and the other of them is zero w is zero, or an integer of from 1 to 21 x is zero, or an integer of from 1 to 4 y is zero, or an integer of from 1 to 2 z is zero, or an integer of from 1 to 4; and u+v+w+x+y+z is an integer of from 1 to 22 the subgroups within the group (2) being in any sequence provided that when the subgroup (CH═CH) is present, then the total number of carbon atoms in said group (2) will be from 10 to 22; and (ii) a therapeutically acceptable vehicle for the ester.

Claim 2

A method for the treatment of a skin disorder in man and other mammals selected from the group consisting of: Ichthyosiform dermatoses, Conradi's syndrome, Localised hyperkeratotic conditions, Dandruff, Callous-forming disorders, Psoriasis, Eczema, Xerosis, Warts, Dermatomycoses, Pityriasis rosea and Pityriasis alba, Lichen planus and Lichen simplex chronicus, Cicatricial alopecia with dry flaky scalp, Darier's disease, Pruritus, Seborrhoeic dermatitis, Seborrhoeic eczema, Acne, and Scabies, said method comprising applying to involved areas of the body a composition comprising: (i) an effective amount of an ester of pyroglutamic acid having the structure: ##STR4## where R is a group: ##STR5## ##STR6## where R' and R" are the same or different and are each represented by H or the group: [(CH.sub.3).sub.u,(CH.sub.2 OH).sub.v, (CH.sub.2).sub.w,(CHCH.sub.3).sub.x,(CHOH).sub.y,(CH═CH).sub.z]--( 2) where either u or v is 1 and the other of them is zero w is zero, or an integer of from 1 to 21 x is zero, or an integer of from 1 to 4 y is zero, or an integer of from 1 to 2 z is zero, or an integer of from 1 to 4; and u+v+w+x+y+z is an integer of from 1 to 22 the subgroups within the group (2) being in any sequence provided that when the subgroup (CH═CH) is present, then the total number of carbon atoms in said group (2) will be from 10 to 22; and (ii) a therapeutically acceptable vehicle for the ester.